PsiOxus Therapeutics Limited Initiates Phase II Clinical Study of Wasting Disease Therapeutic MT-102
Published: Mar 17, 2011
LONDON--(BUSINESS WIRE)--PsiOxus Therapeutics, Ltd. (PsiOxus) announced initiation of a Phase II study of MT-102, a small molecule therapeutic for the treatment of cancer- and age-related wasting. MT-102 is being developed to reverse the effects of cachexia, a wasting disease that accompanies cancer, heart failure, COPD, renal failure, cirrhosis and rheumatoid arthritis, and that is associated with significant morbidity and mortality. MT-102 is also in development for sarcopenia, the age-related loss of muscle mass and strength that affects one in five people by age 60.